



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FISHMAN10A

In re Application of:)	Confirmation No.: 9316
Pnina FISHMAN)	Art Unit:
)	
Appln. No.: 10/689,550)	Examiner:
)	
Filed: October 21, 2003)	Washington, D.C.
)	
For: A3AR AS A MARKER FOR A)	March 22, 2004
DISEASED STATE)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Mail Stop DD
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[XX]before the mailing date of a first Office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., Form PTO/SB/08A) of all patents,

publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

3. Document(s) _____ is (are) not in the English language. In accordance with §1.98(c), Applicant(s) states:

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).


5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:




Sheridan Neimark
Reg. No. 20,520

SN:keb
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\C\cohn\Fishman10A\Pto\ids.fee.doc

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	FISHMAN10A
		Filing Date	October 21, 2003
		First Named Inventor	Pnina FISHMAN
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	FISHMAN10A
Sheet	1	of	1



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AA	BONVINI et al "Nuclear β -catenin displays GSK-3 β - and APC-independent proteasome sensitivity in melanoma cells," <u>Biochimica et Biophysica Acta</u> 1495: 308-318 (2000)	
	AB	FANG et al "Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A," <u>PNAS</u> 97 (22): 11960-11965 (October 24, 2000)	
	AC	FERKEY et al "GSK-3: New Thoughts on an Old Enzyme," <u>Developmental Biology</u> 225: 471-479 (2000)	
	AD	FISHMAN et al "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells," <u>Oncogene</u> 21: 4060-4064 (2002)	
	AE	OLAH et al "The role of receptor structure in determining adenosine receptor activity," <u>Pharmacology & Therapeutics</u> 85: 55-75 (2000)	
	AF	POULSEN et al "Adenosine Receptors: New Opportunities for Future Drugs," <u>Bioorganic & Medicinal Chemistry</u> 6: 619-641 (1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.